NWBO's stuck with retail investors because they are an OTC penny stock. So 99.9% of the shares held by insiders and retail investors. NWBO has been using paid stock pumpers and ghost-written articles to try to build retail investors as they have no other methods. Business media doesn't cover OTC penny stocks.
NWBO MAY has a life prolonging treatment but the clinical data is clearly viewed as suspect. Share price has shown no positive response to the TLD data. Didn't attract any significant media coverage.
Totally tossing out clinical trial protocols/SAP is always suspect. NWBO repeatedly has reported naïve OS data confounding -- always a significant issue. So trial data reality is in question. But some investors will buy on faith.
Market Data 
Markets 
AI
